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OBJECTIVES This study evaluated the prevalence and severity of anemia in patients with congestive heart
failure (CHF) and the effect of its correction on cardiac and renal function and hospitaliza-
tion.
BACKGROUND The prevalence and significance of mild anemia in patients with CHF is uncertain, and the
role of erythropoietin with intravenous iron supplementation in treating this anemia is
unknown.
METHODS In a retrospective study, the records of the 142 patients in our CHF clinic were reviewed to
find the prevalence and severity of anemia (hemoglobin [Hb] ,12 g). In an intervention
study, 26 of these patients, despite maximally tolerated therapy of CHF for at least six
months, still had had severe CHF and were also anemic. They were treated with
subcutaneous erythropoietin and intravenous iron sufficient to increase the Hb to 12 g%. The
doses of the CHF medications, except for diuretics, were not changed during the intervention
period.
RESULTS The prevalence of anemia in the 142 patients increased with the severity of CHF, reaching
79.1% in those with New York Heart Association class IV. In the intervention study, the
anemia of the 26 patients was treated for a mean of 7.2 6 5.5 months. The mean Hb level
and mean left ventricular ejection fraction increased significantly. The mean number of
hospitalizations fell by 91.9% compared with a similar period before the study. The New York
Heart Association class fell significantly, as did the doses of oral and intravenous furosemide.
The rate of fall of the glomerular filtration rate slowed with the treatment.
CONCLUSIONS Anemia is very common in CHF and its successful treatment is associated with a significant
improvement in cardiac function, functional class, renal function and in a marked fall in the
need for diuretics and hospitalization. (J Am Coll Cardiol 2000;35:1737–44) © 2000 by the
American College of Cardiology
The mean hemoglobin (Hb) in patients with congestive
heart failure (CHF) is about 12 g Hb per 100 ml blood (g%)
(1–3), which is considered to be the lower limit of normal in
adult men and postmenopausal women (4). Thus, many
patients with CHF are anemic, and this anemia has been
shown to worsen as the severity of the CHF progresses
(5,6). Severe anemia of any cause can produce CHF, and
treatment of the anemia can improve it (7). In patients with
chronic renal failure (CRF) who are anemic, treatment of
the anemia with erythropoietin (EPO) has improved many
of the abnormalities seen in CHF, reducing left ventricular
hypertrophy (LVH) (8–10), preventing left ventricular di-
lation (11) and, in those with reduced cardiac function,
increasing the left ventricular ejection fraction (LVEF)
(8–10), the stroke volume (12) and the cardiac output (12).
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In view of the high prevalence of anemia in CHF, it is
surprising that we could find no studies in which EPO was
used in the treatment of the anemia of CHF, and the use of
EPO is not included in U.S. Public Health Service guide-
lines of treatment of the anemia of CHF (13). In fact,
anemia has been considered only a rare contributing factor
to the worsening of CHF, estimated as contributing to no
more than 0% to 1.5% of all cases (14–16). Perhaps for this
reason, recent guidelines for the prevention and treatment
of CHF do not mention treatment of anemia at all (17). If
successful treatment of anemia could improve cardiac func-
tion and patient function in CHF, this would have profound
implications, because, despite all the advances made in the
treatment of CHF, it is still a major and steadily increasing
cause of hospitalizations, morbidity and mortality (18–20).
The purpose of this study is to examine the prevalence of
anemia (Hb ,12 g%) in patients with different levels of
severity of CHF and to assess the effect of correction of this
anemia in severe CHF patients resistant to maximally
tolerated doses of CHF medication. A combination of
subcutaneous (SC) EPO and intravenous (IV) iron (Fe) was
used. We have found this combination to be additive in
improving the anemia of CRF (21,22).
METHODS
Patients. The medical records of the 142 CHF patients
being treated in our special outpatient clinic devoted to
CHF were reviewed to determine the prevalence and
severity of anemia and CRF in these patients. These
patients were referred to the clinic either from general
practice or from the various wards in the hospital.
Intervention study. Despite at least six months of treat-
ment in the CHF clinic, 26 of the above patients had
persistent, severe CHF (New York Heart Association
[NYHA] class . III), had a Hb level of ,12 g% and were
resistant to maximally tolerated CHF therapy (including
angiotensin-converting enzyme [ACE] inhibitors, the
alpha-beta-blocker carvedilol, long-acting nitrates, digoxin,
aldactone and oral and IV furosemide. These 26 patients
participated in an intervention study. The mean age was
71.76 6 8.12 years. There were 21 men and 5 women. They
all had a LVEF below 35%, persistent fatigue and shortness
of breath on mild to moderate exertion and often at rest, and
had required hospitalizations at least once during their
follow-up in the CHF clinic for pulmonary edema. In 18 of
the 26 patients, the CHF was associated with ischemic heart
disease either alone in four patients, or with hypertension in
six, diabetes in four, the two together in three, or with
valvular heart disease in one. Of the remaining eight
patients, four had valvular heart disease alone and four had
essential hypertension alone.
Secondary causes of anemia including gastrointestinal
blood loss (as assessed by history and by three negative stool
occult blood examinations), folic acid and vitamin B12
deficiency and hypothyroidism were ruled out. Routine
gastrointestinal endoscopy was not carried out. The study
passed an ethics committee.
Correction of the anemia. All patients received the com-
bination of SC EPO and IV Fe. The EPO was given once
a week at a starting dose of 2,000 IU per week subcutane-
ously, and the dose was increased or decreased as necessary
to achieve and maintain a target Hb of 12 g%. The IV Fe
(Venofer-Vifor International, St. Gallen, Switzerland), a
ferric sucrose product, was given in a dose of 200 mg IV in
150 ml saline over 60 min every week until the serum
ferritin reached 400 mg/liter or the percent Fe saturation
(%Fe Sat: serum iron/total iron binding capacity 3 100)
reached 40% or until the Hb reached 12 g%. The IV Fe was
then given at longer intervals as needed to maintain these
levels.
Medication dose. Except for oral and IV furosemide ther-
apy, the doses of all the other CHF medications, which
were used in the maximum tolerated doses before the
intervention, were kept unchanged during the intervention
period.
Duration of the study. The study lasted for a mean of
7.2 6 5.5 months (range four to 15 months).
Investigations. Visits were at weekly intervals initially and
then at two- to three-week intervals depending on the
patient’s status. This was the same frequency of visits to the
CHF clinic as before the intervention study. A complete
blood count, serum creatinine, serum ferritin and % Fe Sat
were performed on every visit. An electronic device mea-
sured the blood pressure on every visit. The LVEF was
measured by a multiple gated ventricular angiography heart
scan initially and at four- to six-month intervals. Hospital
records were reviewed to compare the number of hospital-
izations during the time the patients were treated for the
anemia with the number of hospitalizations during a similar
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period of time that they were treated in the CHF clinic
before the anemia was treated. Clinic records were reviewed
to evaluate the types and doses of CHF medications used
before and during the study.
The glomerular filtration rate (GFR) was calculated from
the serum creatinine by the formula: 1/serum creatinine in
mg% 3 100 5 GFR in ml/min. The rate of change of the
GFR before and during the intervention period was calcu-
lated by comparing the change in GFR per month in the
year before the intervention with that during the interven-
tion.
Statistical analysis. Mean 6 standard deviation was cal-
culated. One-way analysis of variance (ANOVA) was per-
formed to compare parameter levels between the four
NYHA groups. Hochberg’s method of multiple compari-
sons (23) was used for pair-wise comparison between two
groups. A p value of less than 0.05 was considered statisti-
cally significant. In the intervention study, the significance
of the difference between the initial values and those at the
end of the study for the individual parameters in the 26
treated patients was assessed by paired student’s t test; p ,
0.05 was considered statistically significant. All the statisti-
cal analysis was performed by the SPSS program (Version 9,
Chicago, Illinois).
RESULTS
CHF: the whole study group. The clinical, biochemical
and hematological characteristics of the 142 patients seen in
the clinic are shown in Tables 1 and 2. Sixty-seven patients
(47%) had severe CHF as judged by a NYHA class of IV
(Table 2). Seventy-nine of the 142 patients (55.6%) were
anemic (Hb , 12 g%). The mean Hb level fell progressively
from 13.73 6 0.83 g% in class I NYHA to 10.90 6 1.70 g%
in class IV NYHA (p , 0.01). The percentage of patients
with Hb , 12 g% increased from 9.1% in class I to 79.1%
in class IV.
Fifty eight patients (40.8%) had CRF as defined as a
serum creatinine $1.5 mg%. The mean serum creatinine
increased from 1.18 6 0.38 mg% in class I NYHA, to 2.0 6
1.89 mg% in class IV NYHA, p , 0.001. The percentage of
patients with an elevated serum creatinine ($1.5 mg%)
increased from 18.2% in class I to 58.2% in class IV. The
mean ejection fraction fell from 37.67 6 15.74% in class I
to 27.72 6 9.68% (p , 0.005) in class IV.
The intervention study: medications. The percentage of
patients receiving each CHF medication before and after
the intervention period and the reasons for not receiving
them are seen in Table 3. The main reason for not receiving:
1) ACE inhibitors was the presence of reduced renal
function; 2) carvedilol was the presence of chronic obstruc-
tive pulmonary disease (COPD); 3) nitrates was low blood
pressure and aortic stenosis and 4) aldactone was hyperka-
lemia. The mean doses of the medications are shown in
Table 4. The mean dose of oral furosemide was 200.9 6
120.4 mg/day before and 78.3 6 41.3 mg/day after the
intervention (p , 0.05). The dose of IV furosemide was
164.7 6 178.9 mg/month before and 19.8 6 47.0 mg/
month after the intervention (p , 0.05). The doses of the
Table 1. Initial Characteristics of the 142 Patients With CHF
Seen in the CHF Clinic
Age, years 70.1 6 11.1
Male/female, % 79/21
Associated conditions
Diabetes 28%
Hypertension 64%
Dyslipidemia 72%
Smoking 40%
Main cardiac diagnosis
Ischemic heart disease 74%
Dilated CMP 15%
Valvular heart disease 6%
Hypertension 5%
LVEF, % 32.5 6 12.2
Left atrial area (n , 15 cm2) 31.3 6 10.3
Pulmonary artery pressure
(n , 15 mm Hg)
43.1 6 14.9
Previous hospitalizations/year 3.2 6 1.5
Serum Na, mEq/liter 139.8 6 4.0
Serum creatinine, mg% 1.6 6 1.1
Hemoglobin, g% 11.9 6 1.5
CMP 5 cardiomyopathy; LVEF 5 left ventricular ejection fraction; NYHA 5 New
York Heart Association class.
Table 2. LVEF and Biochemical and Hematological Parameters by NYHA Class in 142 Patients With CHF
NYHA Class
Significantly
Different Pairs*I II III IV
No. of patients (total 142) (%) 11 (7.7) 26 (18.3) 38 (26.8) 67 (47.2)
Hb, g%† 13.73 6 0.83 13.38 6 1.26 11.95 6 1.48 10.90 6 1.70 1–3, 1–4, 2–3, 2–4
Serum creatinine, mg%† 1.18 6 0.38 1.22 6 0.29 1.32 6 0.38 2.00 6 1.89 1–2, 1–3, 1–4
LVEF, %† 37.67 6 15.74 32.88 6 12.41 32.02 6 10.99 27.72 6 9.68 1–4, 2–4
Hb , 12 g%, no. (%) 1 (9.1) 5 (19.2) 20 (52.6) 53 (79.1)
Serum creatinine $1.5 mg%, no. (%) 2 (18.2) 5 (19.2) 12 (31.6) 39 (58.2)
*p , 0.05 at least between the two groups by pair-wise comparison between groups.
†p , 0.05 at least between the groups by ANOVA.
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other CHF medications were almost identical in the two
periods.
Clinical results. DEATHS. There were three deaths dur-
ing the intervention period. An 83-year-old man died
after eight months of respiratory failure after many years
of COPD, a 65-year-old man at eight months of a CVA
with subsequent pneumonia and septic shock and a
70-year-old man at four months of septicemia related to
an empyema that developed after aortic valve replace-
ment.
HEMODIALYSIS. Three patients, a 76-year-old man, an
85-year-old woman and a 72-year-old man, required
chronic hemodialysis after six, 16 and 18 months, respec-
tively. The serum creatinines of these three patients at onset
of the anemia treatment were 4.2, 3.5 and 3.6 mg%,
respectively. All three had improvement in their NYHA
status but their uremia worsened as the renal function
deteriorated, demanding the initiation of dialysis. In no
cases, however, was pulmonary congestion an indication for
starting dialysis.
Functional results (Table 5). During the treatment pe-
riod, the NYHA class fell from a mean of 3.66 6 0.47 to
2.66 6 0.70 (p , 0.05), and 24 had some improvement
in their functional class. The mean LVEF increased from
27.7 6 4.8 to 35.4 6 7.6% (p , 0.001), an increase of
27.8%. Compared with a similar period of time before the
onset of the anemia treatment, the mean number of
hospitalizations fell from 2.72 6 1.21 to 0.22 6 0.65 per
patient (p , 0.05), a decrease of 91.9%. No significant
changes were found in the mean systolic/diastolic blood
pressure.
Hematological results (Table 5). The mean hematocrit
(Hct) increased from 30.14 6 3.12% to 35.9 6 4.22% (p ,
0.001). The mean Hb increased from 10.16 6 0.95 g% to
12.10 6 1.21 g% (p , 0.001). The mean serum ferritin
increased from 177.07 6 113.80 mg/liter to 346.73 6
207.40 mg/liter (p , 0.005). The mean serum Fe increased
from 60.4 6 19.0 mg% to 74.80 6 20.7 mg% (p , 0.005).
The mean %Fe Sat increased from 20.05 6 6.04% to
26.14 6 5.23% (p , 0.005). The mean dose of EPO used
throughout the treatment period was 5,227 6 455 IU per
week, and the mean dose of IV Fe used was 185.1 6
57.1 mg per month. In four of the patients, the target Hb of
12 g% was maintained despite stopping the EPO for at least
four months.
Renal results (Table 5). The changes in serum creatinine
were not significant. The estimated creatinine clearance fell
at a rate of 0.95 6 1.31 ml/min/month before the onset of
treatment of the anemia and increased at a rate of 0.85 6
2.77 ml/min/month during the treatment period.
Table 4. Mean Dose of Each Medication Initially and at the End of the Intervention Period in
the 26 Patients
No. of
Patients Initial Dose Final Dose
Carvedilol (mg/day) 20 26.9 6 15.5 28.8 6 14.5
Captopril (mg/day) 7 69.6 6 40.0 70.7 6 40.4
Enalapril (mg/day) 13 25.7 6 12.5 26.9 6 12.6
Digoxin (mg/day) 25 0.10 6 0.07 0.10 6 0.07
Aldactone (mg/day) 19 61.2 6 49.2 59.9 6 47.1
Long-acting nitrates 23 53.2 6 13.2 54.1 6 14.4
Oral furosemide (mg/day) 26 200.9 6 120.4 78.3 6 41.3*
IV furosemide (mg/month) 26 164.7 6 178.9 19.8 6 47.0*
*p , 0.05 at least vs. before by paired Student’s t test.
Table 3. Number (%) of the 26 Patients Taking Each Type of Medication Before and During
the Intervention Period and the Reason Why the Medication Was Not Used
Medication
No. of
Patients %
Reason for Not Receiving the
Medications (No. of Patients)
ACE inhibitors 20 76.9 CRF (6)
Carvedilol 20 76.9 COPD (3), low BP (2),
bradycardia (1)
Digoxin 25 96.2 second degree heart block (1)
Nitrates 23 88.5 aortic stenosis (1), low BP (2)
Aldactone 19 73.1 hyperkalemia (7)
Oral furosemide 26 100
IV furosemide 26 100
BP 5 blood pressure; CRF 5 chronic renal failure; IV 5 intravenous.
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DISCUSSION
The main findings in the present study are that anemia is
common in CHF patients and becomes progressively more
prevalent and severe as CHF progresses. In addition, in
patients with resistant CHF, the treatment of the associated
anemia causes a marked improvement in their functional
status, ejection fraction and GFR. All these changes were
associated with a markedly reduced need for hospitalization
and for oral and IV furosemide.
The effect of anemia on the ischemic myocardium.
Rather surprisingly, the improvement in cardiac function
occurred, although the baseline anemia was quite modest
(mean Hb 10.16 6 0.95 g%), and the improvement in the
Hb level was only about 2 g%. Animal studies have
demonstrated that the ischemic or hypertrophied heart is
more sensitive to even a small drop of Hb than is the normal
heart, this drop resulting in a marked worsening of the
ischemia and the cardiac function (24). This detrimental
effect of anemia on myocardial function has been borne out
in human studies as well (24,25). This may explain why
correction of the anemia in our patients had such a profound
effect on cardiac function and patient functional class.
Another possible explanation is that EPO may have a direct
effect on improving cardiac muscle function unrelated to the
effect of the anemia (26).
The effect of anemia correction on renal function. Con-
gestive heart failure is often associated with some degree of
CRF (1–3,27–29), and this is most likely due to renal
vasoconstriction and ischemia (28,29). When the anemia is
treated and the cardiac function improves, an increase in
renal blood flow and glomerular filtration is seen (7,28). In
the present study, renal function decreased as the CHF
functional class worsened (Table 2). The rate of deteriora-
tion of renal function was slower during the intervention
period. Treatment of anemia in CRF has been associated
with a rate of progression of the CRF that is either
unchanged (30) or is slowed (31–33). It is possible, there-
fore, that adequate treatment of the anemia in CHF may, in
the long term, help slow down the progression of CRF.
Possible adverse effects of correction of the anemia.
There has been concern, in view of the recent Amgen study
(34), that correction of the Hct to a mean 42% in hemodi-
alysis patients might increase cardiovascular events in those
receiving EPO compared with those maintained at a Hct of
30%. Although there is much uncertainty about how to
interpret this study (35), there is a substantial body of
evidence that shows correction of the anemia up to a Hb of
12 g% (Hct 36%) in CRF on dialysis is safe and desirable
(35–38), and results in a reduction in mortality, morbidity
and in the number and length of hospitalizations. The same
likely holds true for the anemia of CHF with or without
associated CRF. Certainly, our patients’ symptoms were
strikingly improved, as was their cardiac function (LVEF)
and need for hospitalization and diuretics. It remains to be
established if correction of the anemia up to a normal Hb
level of 14 g% might be necessary in order to further
improve the patient’s clinical state.
The role of Fe deficiency and its treatment in the anemia
of CHF. We used the IV Fe together with EPO to avoid
the Fe deficiency caused by the use of EPO alone (38,39).
The Fe deficiency will cause a resistance to EPO therapy
and increase the need for higher and higher doses to
maintain the Hb level (39,40). These high doses will not
only be expensive but may increase the blood pressure
excessively (41). The IV Fe reduces the dose of EPO needed
to correct the anemia, because the combination of SC EPO
and IV Fe has been shown to have an additive effect on
correction of the anemia of CRF (21,22,39,42). Oral Fe,
however, has no such additive effect (39,42). The relatively
low dose of EPO needed to control the anemia in our study
may explain why the blood pressure did not increase
significantly in any patient. We used Venofer, an Fe sucrose
product, as our IV Fe supplement because, in our experience
(21,22,43), it has very few side effects and, indeed, no side
effects with its use were encountered in this study.
Table 5. The Hematological and Clinical Data of the 26 CHF Patients at Onset and at the End of the Intervention Period
Initial Final
Hematocrit, vol% 30.14 6 3.12 35.90 6 4.22*
Hemoglobin, g% 10.16 6 0.95 12.10 6 1.21*
Serum ferritin, mg/liter 177.07 6 113.80 346.73 6 207.40*
Serum iron, mg% 60.4 6 19.0 74.8 6 20.7*
% iron saturation 20.5 6 6.04 26.14 6 5.23*
Serum creatinine, mg% 2.59 6 0.77 2.73 6 1.55
LVEF, % 27.7 6 4.8 35.4 6 7.6*
No. hospitalizations/patient 2.72 6 1.21 0.22 60.65*
Systolic BP, mm Hg 127.1 6 19.4 128.9 6 26.4
Diastolic BP, mm Hg 73.9 6 9.9 74.0 6 12.7
NYHA (0–4) 3.66 6 0.47 2.66 6 0.70*
*p , 0.05 at least vs before by paired Student’s t test.
BP 5 blood pressure; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association.
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Severe CHF patients may be prone to Fe deficiency for
other reasons than just the use of EPO. Poor food intake
(cardiac cachexia) (44), malabsorption (45) or use of pro-
phylactic aspirin (46,47) may also be contributing factors.
Most of the patients in the present study had some degree
of CRF, which is also associated with a reduction in Fe
absorption (48–50). The importance of Fe deficiency in
CHF is seen in the fact that 4 of the 26 patients we studied
were able to maintain the target Hb of 12 g% with IV Fe
alone even after the dose of EPO was stopped for several
months.
Other factors that could contribute to the anemia of
CHF. Another factor that could contribute to the anemia
may be tumor necrosis factor (TNF). Tumor necrosis factor
blood levels have been found to be elevated in CHF (51,52),
have been found to correlate with the severity of the anemia
(51,53) and may cause bone marrow depression (53),
interference in the action of EPO (53) and in the cellular
release and utilization of Fe (54). The use of ACE inhibitors
may also cause a reduction in the Hb levels (55–57),
especially when used in high doses (56), doses that are
usually required in CHF (17).
Study limitations. The major limitations of this study were
the small number of patients treated and the lack of a
control group. Open-label, uncontrolled observations often
yield positive results that, in many cases, are not corrobo-
rated by subsequent controlled studies. Certainly, special
CHF clinics where experts treat these difficult patients have
yielded results far better than those achieved by ordinary
physicians (2,58,59). But in our study, these patients were
being followed at frequent intervals in the CHF clinic for at
least six months before the intervention and were already
receiving the broad range of CHF medications in the
maximally tolerated doses. Yet despite this intensive care
and follow-up, they were still grossly symptomatic and
many were being frequently hospitalized, predominantly
with pulmonary edema. However, the treatment of the
anemia was associated with a reduction in symptoms of
CHF and less hospitalizations, despite the use of much less
diuretics and no change in the doses of any of the other
CHF medications. It seems most likely, therefore, that the
changes that were found in the ejection fraction, functional
class, hospitalization, diuretic use and renal function were
due to the improvement in the anemia. Nevertheless, in
order to clarify more definitively the effect of correction of
anemia on CHF, we have now begun a randomized,
controlled trial.
The cost effectiveness of aggressive therapy of anemia in
CHF. The mean EPO dose needed to reach the target
Hb of 12 g% was about 5,000 IU/week, which costs about
$50/week. Thus, the yearly cost of this dose, if self-
administered, would be about $2,600. The yearly cost of
22 100-mg ampoules of IV Fe (the average number
needed per year in this study to supply the 2,200 mg of IV
Fe needed per year) is about $330, not including the cost
of the IV infusions, which would be required to give this
amount in an outpatient setting. In any case, the cost of
the treatment of the anemia is probably significantly
lower than the cost of any of the alternatives: recurrent
hospitalizations for pulmonary edema, coronary artery
bypass surgery for improving the blood supply to a
hibernating heart, heart transplantation or dialysis.
About 40% of patients starting dialysis for end-stage
renal failure have CHF (60), and the CHF may itself, in
some of these patients, be the major reason for the
dialysis starting earlier (61). Improving cardiac function
in these cases would avoid or postpone the need for
dialysis.
Importance of early treatment of the anemia of CHF. It
is noteworthy, as seen in Table 2, that even in mild CHF
(NYHA functional class II), 5 (19.2%) of the 26 patients in
this group were already anemic. These five all had serum
creatinine levels ranging from 1.9 to 2.4 mg%, indicating
some degree of renal insufficiency. It is possible that
treatment of the anemia in these early stages could, along
with the usual treatment regimen of CHF, help in prevent-
ing both the progression of CRF and progressive congestive
cardiomyopathy.
Conclusions. Many patients with mild CHF and most
patients with moderate to severe CHF are anemic. The
degree of anemia parallels the degree of deterioration of
cardiac and renal function and may contribute to this
deterioration. The correction of the anemia is associated
with an impressive improvement in cardiac function that is
reflected in a marked improvement in the NYHA functional
class, an improvement in renal function and a striking
reduction in hospitalizations and use of oral and IV furo-
semide. Treatment of the anemia with EPO and IV Fe may
be a useful addition to the physicians’ armementarium in
CHF. It would seem from our findings, however, that these
useful tools are grossly underutilized. Clearly, the role of
anemia in the worsening of CHF and the use of EPO and
IV Fe in its correction require further clarification with
controlled trials.
Summary. The prevalence and significance of mild anemia
in CHF and the role of erythropoietin with intravenous iron
supplementation in treating this anemia are unknown. In
142 CHF patients, the prevalence of anemia (Hb , 12 g%)
increased progressively with the severity of CHF. Twenty-
six anemic patients with severe CHF despite maximally
tolerated CHF medications had their anemia corrected with
the EPO-IV/Fe combination. The LVEF increased, the
NYHA class improved, the days of hospitalization and dose
of diuretics required fell and the rate of progression of the
associated renal failure slowed. Correction of mild anemia
may be an important addition to the treatment of CHF.
1742 Silverberg et al. JACC Vol. 35, No. 7, 2000
Erythropoietin for the Anemia of Heart Failure June 2000:1737–44
Acknowledgments
We thank Rina Issaky, Miriam Epstein and Hava Ehren-
feld for their secretarial assistance.
Reprint requests and correspondence: Dr. D. S. Silverberg,
Department of Nephrology, Tel Aviv Medical Center, Weizman
6, Tel Aviv, 64239, Israel.
REFERENCES
1. Haber HL, Leavy JA, Kessler PD, et al. The erythrocyte sedimenta-
tion rate in congestive heart failure. N Engl J Med 1991;324:353–8.
2. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary
intervention to prevent the readmission of elderly patients with
congestive heart failure. N Engl J Med 1995;333:1190–5.
3. Rich MW, Shah AS, Vinson JM, et al. Iatrogenic congestive heart
failure in older adults: clinical course and prognosis. J Am Geriatr Soc
1996;44:638–43.
4. NKF-DOQI clinical practice guidelines for the treatment of anemia of
chronic renal failure. Am J Kidney Dis 1997;30 Suppl:193–240.
5. Maeda K, Tanaka Y, Tsukano Y, et al. Multivariate analysis using a
linear discriminant function for predicting the prognosis of congestive
heart failure. Jpn Circ J 1982;46:137–42.
6. Volpe M, Tritto C, Testa U, et al. Blood levels of erythropoietin in
congestive heart failure and correlation with clinical, hemodynamic,
and hormonal profiles. Am J Cardiol 1994;74:468–73.
7. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris P.
Pathogenesis of edema in chronic anemia: studies of body water and
sodium, renal function, haemodynamics and plasma hormones. Br
Heart J 1993;70:357–62.
8. Low I, Grutzmacher P, Bergmann M, Schoeppe W. Echocardio-
graphic findings in patients on maintenance hemodialysis substituted
with recombinant human erythropoietin. Clin Nephrol 1989;31:26–
30.
9. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe
W. Therapy with recombinant human erythropoietin reduces cardiac
size and improves heart function in chronic hemodialysis patients.
Am J Nephrol 1991;11:54–60.
10. Goldberg N, Lundin AP, Delano B, Friedman EA, Stein RA.
Changes in left ventricular size, wall thickness, and function in anemic
patients treated with recombinant human erythropoietin. Am Heart J
1992;124:424–7.
11. Foley RN, Parfrey PS, Morgan J, et al. A randomized controlled trial
of complete vs partial correction of anemia in hemodialysis patients
with asymptomatic concentric LV hypertrophy or LV dilatation
(abstr). J Am Soc Nephrol 1998;9:208.
12. Linde T, Wikstrom B, Andersson LG, Danielson BG. Renal anaemia
treatment with recombinant human erythropoietin increases cardiac
output in patients with ischaemic heart disease. Scand J Urol Nephrol
1996;30:115–20.
13. Heart failure: management of patients with left-ventricular systolic
dysfunction. Quick reference guide for clinicians. No. 11. AHRCPR
Publication No. 94-0613. Rockville, MD: Agency for Health Care
Policy and Research, Public Health Service, U.S. Department of
Health and Human Services, 1994.
14. Ghali JK, Kadakia S, Cooper R, Ferlinz J. Precipitating factors leading
to decompensation of heart failure. Traits among urban blacks. Arch
Intern Med 1988;148:2013–6.
15. Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of
decompensation in chronic heart failure. Am J Cardiol 1996;78:354–7.
16. Michaelsen A, Konig G, Thimme W. Preventable causative factors
leading to hospital admission with decompensated heart failure. Heart
1998;80:437–41.
17. Packer M, Cohn JN, Abraham WT, et al. Consensus recommenda-
tions for the management of chronic heart failure. Am J Cardiol
1999;83 Suppl 2A:1–38.
18. Massie BM, Shah NB. The heart failure epidemic: magnitude of the
problem and potential mitigating approaches. Curr Opin Cardiol
1996;11:221–6.
19. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart
failure. Eur Heart J 1997;18:208–25.
20. Senni M, Redfield MM. Congestive heart failure in elderly patients.
Mayo Clin Proc 1997;72:453–60.
21. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric
saccharate as an iron supplement in dialysis patients. Nephron 1996;
72:413–7.
22. Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the
treatment of predialysis anemia. Kidney Int 1999;55 Suppl 69:79–85.
23. Hochberg Y. Some conservative generalizations of the T-methods in
simultaneous inference. J Multivar Anal 1974;4:224–34.
24. Carson JL. Morbidity risk assessment in the surgically anemic patient.
Am J Surg 1995;170 Suppl:32–6.
25. Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardio-
vascular disease on surgical mortality and morbidity. Lancet 1996;348:
1055–60.
26. Wald M, Gutnisky A, Borda E, Sterin BL. Erythropoietin modified
the cardiac action of ouabain in chronically anaemic-uraemic rats.
Nephron 1995;71:190–6.
27. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients
admitted to the hospital with congestive heart failure: specialty-related
disparities in practice patterns and outcomes. J Am Coll Cardiol
1997;30:733–8.
28. Anand IS, Chugh SS. Mechanisms and management of renal dys-
function in heart failure. Curr Opin Cardiol 1997;12:251–8.
29. Yoshida H, Yashiro M, Liang P, et al. Mesangiolytic glomerulopathy
in severe congestive heart failure. Kidney Int 1998;53:880–91.
30. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human
erythropoietin on renal function in chronic renal failure predialysis
patients. Am J Kidney Dis 1994;24:777–84.
31. Scharer K, Klare B, Braun A, Dressel P, Gretz N. Treatment of renal
anemia by subcutaneous erythropoietin in children with preterminal
chronic renal failure. Acta Paediatr 1993;82:953–8.
32. Lopez-Gomez JM, Jofre R, Moreno F, Verde E, Valderrabano F.
rHuEPO before dialysis and in dialysed patients. Nephrol Dial
Transplant 1995;10 Suppl 6:31–5.
33. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by
erythropoietin therapy retards the progression of chronic renal failure,
especially in nondiabetic patients. Nephron 1997;77:176–85.
34. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease
who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:
584–90.
35. Macdougall IC, Ritz E. The normal hematocrit trial in dialysis
patients with cardiac disease: are we any less confused about target
hemoglobin? Nephrol Dial Transplant 1998;13:3030–3.
36. Silverberg D, Blum M, Peer G, Iaina A. Anemia during predialysis
period: a key to cardiac damage in renal failure. Nephron 1998;80:1–5.
37. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and
erythropoietin treatment on overall and cardiovascular mortality and
morbidity: the experience of the Lombardy Dialysis Registry. Nephrol
Dial Transplant 1998;13:1642–4.
38. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated
mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610–9.
39. Macdougall IC, Tucker B, Thompson J, et al. A randomized con-
trolled study of iron supplementation in patients treated with eryth-
ropoietin. Kidney Int 1996;50:1694–9.
40. Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P. The use
of Epoetin beta in anemic predialysis patients with chronic renal
failure. Clin Nephrol 1995;44:201–8.
41. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial
Transplant 1995;10 Suppl 2:74–9.
42. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human
erythropoietin doses by the use of chronic intravenous iron supple-
mentation. Am J Kidney Dis 1995;26:41–6.
43. Silverberg DS, Iaina A, Peer G, et al. Intravenous iron supplementa-
tion for the treatment of the anemia of moderate to severe chronic
renal failure patients not receiving dialysis. Am J Kidney Dis 1996;27:
234–8.
44. Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition
in patients with ischemic and nonischemic dilated cardiomyopathy and
congestive heart failure. Am J Cardiol 1994;73:908–10.
45. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat
malabsorption in elderly patients with cardiac cachexia. Age Ageing
1996;25:144–9.
1743JACC Vol. 35, No. 7, 2000 Silverberg et al.
June 2000:1737–44 Erythropoietin for the Anemia of Heart Failure
46. Weil J, Colin JD, Langman M, et al. Prophylactic aspirin and risk of
peptic ulcer bleeding. Br Med J 1995;310:827–30.
47. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose
aspirin in a healthy elderly population. Clin Pharmacol Ther 1993;54:
84–9.
48. Donnelly SM, Posen GA, Ali MA. Oral iron absorption in hemodi-
alysis patients treated with erythropoietin. Clin Invest Med 1991;14:
271–6.
49. Goch J, Birgegard G, Danielson BG, Wikstrom B. Iron absorption in
patients with chronic uremia on maintenance hemodialysis and in
healthy volunteers measured with a simple oral iron load test. Nephron
1996;73:403–6.
50. Kooistra MP, Niemantsverdriet EC, van Es A, et al. Iron absorption
in erythropoietin-treated haemodialysis patients: effects of iron avail-
ability, inflammation and aluminum. Nephrol Dial Transplant 1998;
13:828–8.
51. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated
circulating levels of tumor necrosis factor in severe chronic heart
failure. N Engl J Med 1990;323:236–41.
52. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, Vooletich MT,
Farmer JA, Torre-Amione G. Tumor necrosis factor. A mediator of
disease progression in the failing human heart. Chest 1999;115:
1170–4.
53. Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the
response to erythropoietin in hemodialysis patients. Kidney Intern
1998;54:1337–43.
54. Feelders RA, Vreugdenhil G, Eggermont AMM, Kuiper-Kramer PA,
Van Eijk HG, Swaak AJG. Regulation of iron metabolism in the
acute-phase response: interferon and tumour necrosis factor induce
hypoferraemia, ferritin production and a decrease in circulating trans-
ferrin receptors in cancer patients. Eur J Clin Invest 1998;28:520–7.
55. Horl WH. Is there a role for adjuvant therapy in patients being treated
with epoetin? Nephrol Dial Transplant 1999;14 Suppl 2:50–60.
56. Albitar S, Genin R, Fen-Chong M, Serveauz M-O, Bourgeon B.
High dose enalapril impairs the response to erythropoietin treatment
in haemodialysis patients. Nephrol Dial Transplant 1998;13:1206–10.
57. Erturk S, Nergizoglu G, Ates K et al. The impact of withdrawing
ACE inhibitors on erythropoietin responsiveness and left ventricular
hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999;
14:1912–6.
58. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a
comprehensive heart failure management program on hospital read-
mission and functional status of patients with advanced heart failure.
J Am Coll Cardiol 1997;30:725–32.
59. Cline CMJ, Israelsson BYA, Willenheimer RB, Broms K, Erhardt
LR. Cost effective management programme for heart failure reduces
hospitalisation. Heart 1998;80:442–6.
60. US Renal Data System. Comorbid conditions and correlations with
mortality risk among 3,999 incident hemodialysis patients. Am J
Kidney Dis 1992;20:32–8.
61. Elhalel-Dranitzki M, Rubinger D, Moskovici A, et al. CAPD to
improve quality of life in patients with refractory heart failure. Nephrol
Dial Transplant 1998;13:3041–2.
1744 Silverberg et al. JACC Vol. 35, No. 7, 2000
Erythropoietin for the Anemia of Heart Failure June 2000:1737–44
